Renin angiotensin system inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Renin-Angiotensin System Inhibitors: Efficacy, Safety, and Clinical Implications
Introduction to Renin-Angiotensin System Inhibitors
Renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), are widely used in the management of hypertension, chronic kidney disease (CKD), and cardiovascular diseases. These medications work by inhibiting the RAS, which plays a crucial role in regulating blood pressure and fluid balance.
Efficacy in Chronic Kidney Disease
Impact on Kidney Function
RAS inhibitors are known to slow the progression of mild to moderate CKD. However, their role in advanced CKD is more complex. A study found that discontinuing RAS inhibitors in patients with advanced CKD did not significantly affect the long-term rate of eGFR decline compared to those who continued the therapy . This suggests that while RAS inhibitors are beneficial in early stages, their discontinuation in advanced stages may not drastically alter disease progression.
Comparative Efficacy of ACE Inhibitors and ARBs
A Bayesian network meta-analysis revealed that both ACE inhibitors and ARBs significantly reduce the risk of kidney failure and major cardiovascular events in CKD patients. However, ACE inhibitors were found to be superior to ARBs in reducing all-cause mortality . This indicates that ACE inhibitors might be the preferred choice in managing CKD.
Cardiovascular Outcomes
Mortality and Cardiovascular Events
RAS inhibitors have a well-established role in reducing cardiovascular morbidity. A meta-analysis of randomized clinical trials demonstrated that ACE inhibitors significantly reduce all-cause mortality in hypertensive patients, whereas ARBs did not show a similar benefit . This highlights the importance of ACE inhibitors in improving survival rates among hypertensive individuals.
Use in Hypertensive COVID-19 Patients
Concerns were raised about the use of RAS inhibitors during the COVID-19 pandemic due to their potential to increase ACE2 expression, a receptor for SARS-CoV-2. However, systematic reviews and meta-analyses have shown that RAS inhibitors are associated with a lower risk of mortality and ventilatory support in hypertensive COVID-19 patients, suggesting that these medications should not be discontinued during the pandemic Wang2020Baral2020.
Safety and Adverse Effects
Hyperkalemia Risk
One of the significant adverse effects of RAS inhibitors is hyperkalemia, especially in patients with heart failure or CKD. The incidence of hyperkalemia is higher with dual RAS inhibition and in patients with underlying conditions, but the absolute changes in serum potassium levels are generally small and manageable with close monitoring .
Comparison with Other Antihypertensive Classes
When compared to other first-line antihypertensive drugs, RAS inhibitors show varying efficacy. For instance, they are associated with a lower risk of heart failure but a higher risk of stroke compared to calcium channel blockers. Similarly, they increase the risk of heart failure and stroke compared to thiazides but reduce total cardiovascular events compared to beta-blockers . These differences highlight the need for personalized treatment plans based on individual patient profiles.
Conclusion
RAS inhibitors, particularly ACE inhibitors, play a crucial role in managing hypertension, CKD, and cardiovascular diseases. They offer significant benefits in reducing kidney failure, cardiovascular events, and mortality. Despite concerns about hyperkalemia and their use during the COVID-19 pandemic, the overall evidence supports their continued use with appropriate monitoring. Personalized treatment strategies should be employed to maximize benefits and minimize risks for individual patients.
Sources and full results
Most relevant research papers on this topic